Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update

Core Insights - SeaStar Medical's QUELIMMUNE™️ demonstrates potential cost savings and improved outcomes for pediatric patients with acute kidney injury (AKI) [1][2] - The device has shown a projected cost savings of approximately $30,000 per hospitalization compared to historical averages for children not treated with QUELIMMUNE [2][3] - QUELIMMUNE therapy achieves cost neutrality starting at 6 days of treatment, with a high survival rate of 77% in treated children [3] Company Overview - SeaStar Medical is a commercial-stage medical device company focused on reducing hyperinflammation's impact on vital organs through innovative therapies [6] - The Selective Cytopheretic Device (SCD) is designed to target proinflammatory cells and promote organ recovery, having received FDA Breakthrough Therapy Designation for multiple indications [5] - QUELIMMUNE, the pediatric version of the SCD, was approved under a Humanitarian Device Exemption in February 2024 for critically ill children with AKI [5] Industry Context - The American Society of Nephrology's Kidney Week 2024 serves as a platform for presenting advancements in nephrology, with over 12,000 professionals expected to attend [4] - Acute Kidney Injury (AKI) poses significant healthcare challenges, often leading to multi-organ dysfunction and increased healthcare costs due to prolonged ICU stays and reliance on dialysis [4]